Drug Approval | March 25, 2022
Japan approves BMS’ Breyanzi application for relapsed large B-cell lymphoma
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
A total of 49 projects have been approved so far for 33 critical APIs with a committed investment of Rs 3,685 crore
A total of 21 applicants have been approved for 49 products, with the potential to utilize an incentive amount of Rs. 2541 crore
SAATH is a ‘One AXA’ public health initiative between AXA France Vie, AXA GO Business Operations, and AXA XL
Commits to plant 5000 trees in phase 1 with its partner SankalpTaru Foundation
First advanced hybrid closed-loop insulin pump system in India features automatic insulin delivery, automatic correction boluses, and bluetooth connectivity
If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
The bulk drug plants that have already been commissioned include CDA, para amino phenol, atorvastatin, sulfadiazine, oxcarbazepine, levofloxacin, carbidopa and levodopa
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
Subscribe To Our Newsletter & Stay Updated
